NAV — Navco Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$0.57m
- CA$0.63m
Annual income statement for Navco Pharmaceuticals, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2022 June 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS/A |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 0.1 | 2.15 | 1.72 |
| Operating Profit | -0.1 | -2.15 | -1.72 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -0.094 | -2.15 | -1.72 |
| Net Income After Taxes | -0.094 | -2.15 | -1.72 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.094 | -2.15 | -1.72 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.094 | -2.15 | -1.72 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.036 | -0.049 | -0.031 |